EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical trajectories and medication response in TBC1D24 ‐related epilepsies

Ealing Mondragon iD, Jan H Magielski iD, Bintou Bane iD, JoeyLynn Nolan, Sarah M Ruggiero iD, Dallas Armstrong iD, Susan Arnold iD, Deepa Sirsi iD, Ingo Helbig iD, Jillian L McKee iD

Epilepsia · 2026

DOI: 10.1111/epi.70013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, 2026. Verfasst von Ealing Mondragon und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsy, Carrier Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, Children's Hospital of Philadelphia, University of Pennsylvania Orphan Disease Center Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Biallelic variants in TBC1D24 represent a rare cause of epilepsy and neurodevelopmental disorders, including severe developmental and epileptic encephalopathies. Here, we present the first attempt to delineate the longitudinal disease histories and effectiveness of antiseizure medications (ASMs) in TBC1D24 ‐related disorders.

Methods

We performed an analysis of the electronic medical record data of 15 individuals with TBC1D24 ‐related disorders. Using the Human Phenotype Ontology, we recorded neurological histories and medication responses across 197 patient‐years of information.

Results

Individuals with TBC1D24 ‐related disorders presented with a range of seizure types with a median age at seizure onset of 3 months—most frequently (73%) with focal myoclonic seizures both sparing and impairing consciousness. We report the maximum prevalence (MP) of various features as percentages of individuals reporting a given phenotype at that time point, compared to all those with available data at that time point. MP of focal seizures was at 6.25 and 7.75 years of age (88%), myoclonic seizures (focal and generalized) between 9 and 10 years of age (80%), and status epilepticus at 9 and 11 months of age (90%). Individuals also presented with a range of movement disorders. The MP of non‐epileptic myoclonus was 100% at 1 and 17 months of age, tremor at 14 months of age (67%), ataxia at 7.25 years of age (45%), and episodic hemiplegia at 3.25 years of age (20%). The use of phenobarbital, oxcarbazepine, and topiramate showed the most promise in seizure management when compared to other ASMs. Everolimus, phenobarbital, and oxcarbazepine proved more effective in maintaining seizure freedom or reducing seizure frequencies in focal and myoclonic seizures compared to other ASMs. Significance TBC1D24 ‐related disorders are characterized by severe and pharmacoresistant epilepsy, with status epilepticus, focal seizures, and myoclonic seizures early in life. This study offers novel insights into the longitudinal disease course and treatment response in TBC1D24 ‐related disorders, a critical first step toward clinical trial readiness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsEpilepsyCarrier ProteinsHumansMaleFemaleChildAdolescentAdultChild, PreschoolYoung AdultInfantPhenotypeLongitudinal StudiesTreatment OutcomeGTPase-Activating Proteins

Stichwörter der Autor:innen

TBC1D24Human Phenotype Ontologydevelopmental and epileptic encephalopathyepilepsygenetics

Substanzen

AnticonvulsantsTBC1D24 protein, humanCarrier ProteinsGTPase-Activating Proteins

Autor:innen und Institutionen

  • Department of Pediatrics and Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • The Epilepsy NeuroGenetics Initiative (ENGIN), Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Department of Biomedical and Health Informatics (DBHi), Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • TBC1D24 Foundation, Milford, Pennsylvania, USA.
  • Yale Medicine, New Haven, Connecticut, USA.

ORCID-Profile: Ealing Mondragon, Jan H Magielski, Bintou Bane, Sarah M Ruggiero, Dallas Armstrong, Susan Arnold, Deepa Sirsi, Ingo Helbig, Jillian L McKee

Förderung

  • NINDS NIH HHS
  • Children's Hospital of Philadelphia
  • University of Pennsylvania Orphan Disease Center Grant
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Mondragon, E., Magielski, J. H., Bane, B., Nolan, J., Ruggiero, S. M., Armstrong, D., Arnold, S., Sirsi, D., Helbig, I., & McKee, J. L. (2026). Clinical trajectories and medication response in TBC1D24 ‐related epilepsies. Epilepsia. https://doi.org/10.1111/epi.70013

Vancouver

Mondragon E, Magielski JH, Bane B, Nolan J, Ruggiero SM, Armstrong D, et al. Clinical trajectories and medication response in TBC1D24 ‐related epilepsies. Epilepsia. 2026. doi:10.1111/epi.70013

BibTeX
@article{Mondragon2026,
  author = {Mondragon, Ealing and Magielski, Jan H and Bane, Bintou and Nolan, JoeyLynn and Ruggiero, Sarah M and Armstrong, Dallas and Arnold, Susan and Sirsi, Deepa and Helbig, Ingo and McKee, Jillian L},
  title = {Clinical trajectories and medication response in TBC1D24 ‐related epilepsies},
  journal = {Epilepsia},
  year = {2026},
  doi = {10.1111/epi.70013}
}
Kostenlos starten →